Take a trial of UK to unlock this pageFind out more
© Stockopedia 24th February, 2017

Smith & Nephew

SN. 1206p 0.0  0.0%
5:04pm 2.00k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2011 2012 2013 2014 2015 2016 2017E 2018E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 30th Mar, paid: 10th May more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +4.8%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2016, Smith & Nephew plc revenues increased 1% to $4.67B. Net income increased 91% to $784M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Share of losses from associates decrease of 81% to $3M (expense). Dividend per share decreased from $0.31 to $0.19. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
A-
A-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2017
31st Dec 2018

Price Target: $16.1
(+7.31% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +6.0% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
14 brokers Broker Consensus Trend
Broker Recommendations for Smith & Nephew
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 8 4 3

Named Brokers and Analysts
Jefferies Chris Cooper , Credit Suisse Christoph Gretler , BERNSTEIN , Investec Bank (UK) Plc Cora McCallum , Canaccord Genuity William Plovanic , Brean Capital, LLC Jason Wittes , Northland Securities , Numis Securities Sally Taylor , Edison Investment Research Linda Pomeroy , Societe Generale Justin Smith , Berenberg Tom Jones , Morningstar, Inc. Debbie Wang , Day by Day Valérie GASTALDY , Cantor Fitzgerald Europe Brian White ,

Profile Summary

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives. Its knee systems include LEGION/GENESIS II Total Knee System and JOURNEY II Family of Active Knees. Its hip systems include the ANTHOLOGY Hip System, SYNERGY Hip System, the SMF Femoral Hip System, POLARSTEM Femoral Hip System, the R3 Acetabular System and the POLARCUP Dual Mobility Hip System. Its Sports Medicine Joint Repair products include the FAST-FIX family of meniscal repair systems, the ENDOBUTTON family for knee ligament reconstruction, HEALICOIL PK, FOOTPRINT PK and TWINFIX Suture anchors for repairs of the hip and rotator cuff.

Directors: Olivier Bohuon (CEO) 55, Rodrigo Bianchi (CEX) 56, Diogo Moreira-Rato (CEX) 55, Cyrille Petit (CEX) 45, Matthew Stober (CEX) 48, Glenn Warner (CEX) 53, Elga Lohler (CHO) 48, John Campo (OTH) 61, Michael Frazzette (OTH) 54, Susan Swabey (SEC) 54, Roberto Quarta (NEC) 66, Vinita Bali (NID) 61, Ian Barlow (NID) , Virginia Bottomley (NID) 68, Erik Engstrom (NID) 52,

No. of Employees: 14,686 No. of Shareholders: n/a


Last Annual December 31st, 2016
Last Interim December 31st, 2016
Incorporated February 17, 1937
Public Since August 13, 1951
Shares in Issue 874,929,862
Free Float 867.2m (99.1%)

SN. Share Price Performance SN.Quote
1206p
0.0  0.0%
Traded 5:04pm · Minimum 15 min delayed · NMS: 2.00k

Latest SN. News Announcements (delayed)

Upcoming SN. Events
Thursday 30th March, 2017
Dividend For SN.
Thursday 6th April, 2017
Smith & Nephew PLC Annual Shareholders Meeting
Friday 5th May, 2017
Q1 2017 Smith & Nephew PLC Trading Statement Release
Thursday 27th July, 2017
Q2 2017 Smith & Nephew PLC Earnings Release

Recent ↓
Thursday 9th February, 2017
Q4 2016 Smith & Nephew PLC Earnings Call
Thursday 9th February, 2017
Q4 2016 Smith & Nephew PLC Earnings Release
Wednesday 16th November, 2016
Smith & Nephew PLC at Deutsche Bank Depositary Receipts Virtual Investor Conference
Thursday 3rd November, 2016
Q3 2016 Smith & Nephew PLC Trading Statement Call
Thursday 3rd November, 2016
Q3 2016 Smith & Nephew PLC Trading Statement Release
Thursday 6th October, 2016
Dividend For SN.L
Wednesday 5th October, 2016
Dividend For SNN
Thursday 28th July, 2016
Q2 2016 Smith & Nephew PLC Earnings Call
Thursday 28th July, 2016
Q2 2016 Smith & Nephew PLC Earnings Release
Thursday 28th July, 2016
Q2 2016 Smith & Nephew PLC Trading Statement Release
Thursday 9th June, 2016
Smith & Nephew PLC at Deutsche Bank ADR Virtual Investor Conference
Thursday 5th May, 2016
Q1 2016 Smith & Nephew PLC Trading Statement Call
Thursday 5th May, 2016
Q1 2016 Smith & Nephew PLC Trading Statement Release
Thursday 21st April, 2016
Dividend For SN.L
Wednesday 20th April, 2016
Dividend For SNN
Thursday 14th April, 2016
Smith & Nephew PLC Annual Shareholders Meeting
Tuesday 1st March, 2016
Smith & Nephew PLC at Canaccord Genuity Musculoskeletal Conference
Thursday 4th February, 2016
Q4 2015 Smith & Nephew PLC Earnings Call
Thursday 4th February, 2016
Q4 2015 Smith & Nephew PLC Earnings Release
Wednesday 18th November, 2015
Smith & Nephew PLC at Jefferies Autumn Global Healthcare Conference


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2017.


Should you buy SN.

Access SN. Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder